Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease.

Abstract

The impact of COVID-19 is regressing. As society begins to return to pre-pandemic norms, there remains a small but important population in whom COVID-19 is a concern, which includes patients with systemic autoimmune rheumatic disease. These patients were at increased risk of severe COVID-19 during the pandemic,1 and current evidence suggests that they continue to be at risk of adverse outcomes. A major evolution in the management of COVID-19 is the use of direct antivirals and monoclonal antibodies.